Omni Bio Pharmaceutical Inc

Omni Bio Pharmaceutical — Investor Presentation (February 2013)

20 slides from Omni Bio Pharmaceutical's investor presentation, Feb 12, 2013

  1. Slide 1: An Overview of Omni Bio Pharmaceutical, Inc.

    Slide 1: An Overview of Omni Bio Pharmaceutical, Inc.

    An Overview of Omni Bio Pharmaceutical, Inc. A Company Focused on Monetizing Assets and Creating Breakthrough Therapies Bruce Schneider, Ph.D. February, 2013 %

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements Except for the historical information contained herein, the matters discussed in this presentation are forward-looking statements. The forward-looking statements in this presentation are based on information available to us as of the date any such statements are made and w

  3. Slide 3: Topics to be Addressed

    Slide 3: Topics to be Addressed

    Topics to be Addressed e Overview e Our Team e Plasma Product Profile/Licensing e A Better Solution: Recombinant Fc-AAT e Fc-AAT Science Highlights e Fc-AAT Development Plan e Financing Needs/Plans e Summary 3 OF niBio

  4. Slide 4: Quick Overview of Omni

    Slide 4: Quick Overview of Omni

    ~ Quick Overview of Omni e Public company since 2009 (symbol OMBP.OB) e Initially focused on promoting & licensing new uses of plasma-derived alpha-1 antitrypsin (p-AAT) e Now developing “Enbrel-like” recombinant Fc fusion proteins (Fc-AATs) e Safety/efficacy experience with p-AAT expected to inform

  5. Slide 5: Our Team

    Slide 5: Our Team

    Our Team e CEO - Bruce Schneider, PhD e Over 35 years experience in drug development e Mostrecently EVP & Chief of Research Operations at Wyeth/Pfizer e CSO- Charles Dinarello, MD e World recognized “father” of cytokine biology ¢ Current affiliations with Univ of Colorado and Radboud Univ (Netherlan

  6. Slide 6: What's Plasma-derived AAT (p-AAT)?

    Slide 6: What's Plasma-derived AAT (p-AAT)?

    ~What’s Plasma-derived AAT (p-AAT)? e Currently approved to treat AAT-deficient patients e Emphysema, COPD e Product characteristics e |Vinfusions required once per week e 25 year safety record e Limited supply, high cost (~$100,000/patient-year) ¢ Total market size >$600M e Multiple new uses discov

  7. Slide 7: Indications Supported by Emerging Clinical Data

    Slide 7: Indications Supported by Emerging Clinical Data

    cations Supported by | Emerging Clinical Data* e Diabetes mellitus e GVHD and other non-organ transplantation e Radioprotection e Certain bacterial infections e Certain viral infections e Myocardial remodeling e Inflammatory Bowel Disease (GI wasting diseases) “Licensed patents issued or pending in

  8. Slide 8: p-AAT Clinical Trials

    Slide 8: p-AAT Clinical Trials

    p-AAT Clinical Trials ° Type 1 Diabetes e Three pilot studies completed (Omni Bio, Immune Tolerance Network, Kamada) e Loss of pancreatic beta cell function (essential for insulin production) slowed/halted in some patients e Higher, more frequent dosing being studied e Graft vs Host Disease (GVHD) A

  9. Slide 9: A Better Solution: Fc-AAT

    Slide 9: A Better Solution: Fc-AAT

    A Better Solution: Fo-AAT e Dr. Dinarello et al have been studying various Fc-AATs for past two years e Key attributes of lead molecule: e Over 100x more potent than p-AAT in vitro e 40-50x more potent in various whole animal models e Longer duration of effect seen in some models e Able to be self-a

  10. Slide 10: Fc-AAT is a Dimeric Fusion Construct

    Slide 10: Fc-AAT is a Dimeric Fusion Construct

    Fc-AAT is a Dimeric Fusion Construct Fc Fc 10 Q Configuration similar to Enbrel O Fc fusion molecules inherently designed to extend duration of action O Fc fusion molecules well- known to regulatory authorities OF niBio

  11. Slide 11: Data Highlights – Type 1 Diabetes

    Slide 11: Data Highlights – Type 1 Diabetes

    - Data Highlights — Type 1 Diabetes AAT treatment restores insulin content to islet cells Insulin Glucagon g° A Ber g Control 3 —LinsulintAAT amet 2 4 Insulin Control 8 é c 0 6 100 160 200 250 300 p-AAT Treated a I Days after initial therapy , i i Islet histology of spontaneous diabetic NOD mice a r

  12. Slide 12: Data Highlights - GVHD

    Slide 12: Data Highlights - GVHD

    Data Highlights - GVHD AAT reduces mortality from GvHD in mouse transplant model 100 . 80 => SS 3 = 60 “@ Syngeneic Transplant g ~ Allogeneic Transplant > 40 + Human Albumin £ > a Allogeneic Transplant a + p-AAT 20 0 0 10 20 30 40 50 60 70 Days after BMT Tawara| et al. PNAS 2012;109:564-569, of . In

  13. Slide 13: Data Highlights - Cardiac Re-Modeling

    Slide 13: Data Highlights - Cardiac Re-Modeling

    Data Highlights - Cardiac Re-Modeling AAT reduces acute myocardial infarct size in mouse model Albumin Infarct Infarct N=6pergroup * *P<0.05vssham ** P<0.05 vs Albumin Toldo et al. (2011) J Mol Cell Cardiol §1(2): 244-61 z OF niBio

  14. Slide 14: ITN's Type 1 Diabetes Pilot Study

    Slide 14: ITN's Type 1 Diabetes Pilot Study

    ITN’s Type 1 Diabetes Pilot Study C-peptide Mean 2-hour AUC (pmolimL) Results indicate stabilization of C-peptide levels (a measure of insulin-producing pancreatic beta cell function) 2.0 == Pediatric 7 = Adutt 1.5 Mean change from baseline. 1.0 + Adult: +0.013 (p=0.852) + Pediatric: -0.191 (p=0.148

  15. Slide 15: Expected C-peptide Decline in T1D

    Slide 15: Expected C-peptide Decline in T1D

    xpected C-peptide Decline in T1D 1.0: ri 08: 7” z 0.6: os V8 tas y 2G ' 0.0+ C) 6 2 18 4 . ae * Month hon crn Om) prs ay ama mae Predicted C-peptide decline during Decline is faster in younger subjects (< 21 yrs) first 12 months is 0.3 pmol/mL/year Greenbaum et al (2012) Diabetes 61: 2066-2073 5 OP

  16. Slide 16: Lead Indications Under Consideration

    Slide 16: Lead Indications Under Consideration

    eve Unusually Broad Lead Indications Under Consideration Disease Market Size (US/EU) Type 1 Diabetes (Early Onset) >$1B Graft vs Host Disease ~$500M Gout (Treatment Refractory) >$1B Options For Life Cycle Management Disease Market Size (US/EU) Rheumatoid Arthritis >$1B Inflammatory Bowel Disease >$1

  17. Slide 17: Fc-AAT Early Development Plan (Overview)

    Slide 17: Fc-AAT Early Development Plan (Overview)

    zon 2012 2013 2014 2015 2016 a @ @ @ a @ 8 ow a @ OB a a ae Oe le Fc-AAT Early Development Plan (Overview) © . Selection of Candidate Molecule Pre-Clinical Pharmacology & Toxicology (NNN Establish MCB (LEED Early Process Dev, GD Early Analytical Assay Dev. Early Formulation Dev. (ED GMP Drug Product

  18. Slide 18: Value-Enhancing Decision Points

    Slide 18: Value-Enhancing Decision Points

    Value-Enhancing Decision Points e Activity/decision point 1 (4a2013) « Process/formulation/analytical development « Ancillary pharmacology & pilot tox studies « GMP clinical trial material (drug product) e Decision point 2 (2a2014) « IND enabling toxicology « IND submission e Decision point 3 (42014

  19. Slide 19: Corporate Information

    Slide 19: Corporate Information

    ~ Corporate Information e Stock symbol OMBP.OB e Closing stock price (2/5/13) $0.40 e 52-week range $0.17-2.52 e Shares outstanding 32 million e Fully diluted shares 54.7 million e Estimated public float shares 18 million e Market capitalization (2/5/13) $12.8 million e Fiscal year-end March 31 e Ca

  20. Slide 20: Omni Summary

    Slide 20: Omni Summary

    ~Omni Summary e Solid strategy for monetizing IP assets e Recombinant Fc-AAT has very broad, high value potential e Our plan for developing Fc-AAT is e Well-defined and predictably executed e Supported by a new management team and advisors with deep experience e The pathway to a highly valuable clin

Source: SEC EDGAR · 8-K filed Feb 12, 2013

More decks from Omni Bio Pharmaceutical Inc